sBCMA-Fc V3 treatment effectively reduced DLBCL cell growth in a dose-dependent manner, suggesting these cells rely on BAFF for growth and survival (Fig. 5 I). The gene discussed is TNFSF13B; the disease is diffuse large B-cell lymphoma.